Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
BioPharma Dive1d
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
The Citizen3d
After investigation, Covid vaccine mandates just look bad, even corrupt
In last week’s column, I told you how the 2024 General Election (early voting has started) could lead to healthier, smarter, and longer lives for all of us (see: ...
PipelineReview.com1d
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK, NY, USA I2, 2024 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® ...
McKnight's Long-Term Care News1d
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
LEADERSHIP Newspaper15h
Bill Gates To Stand Trial Over COVID-19 Vaccine Claims
A Dutch court ruled on Wednesday that billionaire and global vaccine proponent, Bill Gates, must stand trial in the ...
FDA asks Texas court to shut down COVID-19 vaccine records lawsuit
The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to ...
BioPharma Dive10h
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...
FiercePharma1d
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
pharmaphorum5d
Pfizer cut vaccine production targets because of raw material shortage - reports
Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw ... according to a regularly updated document from the World Health Organization.
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
pharmaphorum8d
GSK turns its guns on Moderna in mRNA jab patent dispute
The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it ...